vs
FIVE BELOW, INC（FIVE）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
FIVE BELOW, INC的季度营收约是Revvity的1.3倍（$1.0B vs $772.1M），Revvity净利率更高（12.7% vs 3.5%，领先9.2%），FIVE BELOW, INC同比增速更快（23.1% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-133.2M），过去两年Revvity的营收复合增速更高（9.0% vs -11.9%）
Five Below是美国特色折扣礼品连锁品牌，2002年成立，总部位于宾夕法尼亚州费城，主要面向青少年消费群体，旗下绝大多数商品定价不超过5美元，另有少量精选商品最高定价40美元，目前在全美拥有超过1850家线下门店。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FIVE vs RVTY — 直观对比
营收规模更大
FIVE
是对方的1.3倍
$772.1M
营收增速更快
FIVE
高出17.2%
5.9%
净利率更高
RVTY
高出9.2%
3.5%
自由现金流更多
RVTY
多$294.9M
$-133.2M
两年增速更快
RVTY
近两年复合增速
-11.9%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $772.1M |
| 净利润 | $36.5M | $98.4M |
| 毛利率 | 33.8% | — |
| 营业利润率 | 4.2% | 14.5% |
| 净利率 | 3.5% | 12.7% |
| 营收同比 | 23.1% | 5.9% |
| 净利润同比 | 2063.9% | 3.9% |
| 每股收益（稀释后） | $0.66 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FIVERVTY
| Q4 25 | $1.0B | $772.1M | ||
| Q3 25 | $1.0B | $698.9M | ||
| Q2 25 | $970.5M | $720.3M | ||
| Q1 25 | $1.4B | $664.8M | ||
| Q4 24 | $843.7M | $729.4M | ||
| Q3 24 | $830.1M | $684.0M | ||
| Q2 24 | $811.9M | $691.7M | ||
| Q1 24 | $1.3B | $649.9M |
净利润FIVERVTY
| Q4 25 | $36.5M | $98.4M | ||
| Q3 25 | $42.8M | $46.7M | ||
| Q2 25 | $41.1M | $53.9M | ||
| Q1 25 | $187.5M | $42.2M | ||
| Q4 24 | $1.7M | $94.6M | ||
| Q3 24 | $33.0M | $94.4M | ||
| Q2 24 | $31.5M | $55.4M | ||
| Q1 24 | $202.2M | $26.0M |
毛利率FIVERVTY
| Q4 25 | 33.8% | — | ||
| Q3 25 | 33.3% | 53.6% | ||
| Q2 25 | 33.4% | 54.5% | ||
| Q1 25 | 40.2% | 56.5% | ||
| Q4 24 | 30.6% | — | ||
| Q3 24 | 32.7% | 56.3% | ||
| Q2 24 | 32.5% | 55.7% | ||
| Q1 24 | 41.2% | 54.6% |
营业利润率FIVERVTY
| Q4 25 | 4.2% | 14.5% | ||
| Q3 25 | 5.1% | 11.7% | ||
| Q2 25 | 5.2% | 12.6% | ||
| Q1 25 | 17.7% | 10.9% | ||
| Q4 24 | -0.1% | 16.3% | ||
| Q3 24 | 5.0% | 14.3% | ||
| Q2 24 | 4.5% | 12.4% | ||
| Q1 24 | 20.1% | 6.8% |
净利率FIVERVTY
| Q4 25 | 3.5% | 12.7% | ||
| Q3 25 | 4.2% | 6.7% | ||
| Q2 25 | 4.2% | 7.5% | ||
| Q1 25 | 13.5% | 6.4% | ||
| Q4 24 | 0.2% | 13.0% | ||
| Q3 24 | 4.0% | 13.8% | ||
| Q2 24 | 3.9% | 8.0% | ||
| Q1 24 | 15.1% | 4.0% |
每股收益（稀释后）FIVERVTY
| Q4 25 | $0.66 | $0.86 | ||
| Q3 25 | $0.77 | $0.40 | ||
| Q2 25 | $0.75 | $0.46 | ||
| Q1 25 | $3.40 | $0.35 | ||
| Q4 24 | $0.03 | $0.77 | ||
| Q3 24 | $0.60 | $0.77 | ||
| Q2 24 | $0.57 | $0.45 | ||
| Q1 24 | $3.64 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $524.5M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.0B | $7.3B |
| 总资产 | $4.8B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FIVERVTY
| Q4 25 | $524.5M | $919.9M | ||
| Q3 25 | $670.2M | $931.4M | ||
| Q2 25 | $624.0M | $991.8M | ||
| Q1 25 | $528.8M | $1.1B | ||
| Q4 24 | $216.6M | $1.2B | ||
| Q3 24 | $327.7M | $1.2B | ||
| Q2 24 | $369.6M | $2.0B | ||
| Q1 24 | $460.1M | $1.7B |
股东权益FIVERVTY
| Q4 25 | $2.0B | $7.3B | ||
| Q3 25 | $1.9B | $7.4B | ||
| Q2 25 | $1.9B | $7.6B | ||
| Q1 25 | $1.8B | $7.6B | ||
| Q4 24 | $1.6B | $7.7B | ||
| Q3 24 | $1.6B | $7.9B | ||
| Q2 24 | $1.6B | $7.9B | ||
| Q1 24 | $1.6B | $7.8B |
总资产FIVERVTY
| Q4 25 | $4.8B | $12.2B | ||
| Q3 25 | $4.6B | $12.1B | ||
| Q2 25 | $4.5B | $12.4B | ||
| Q1 25 | $4.3B | $12.4B | ||
| Q4 24 | $4.2B | $12.4B | ||
| Q3 24 | $4.0B | $12.8B | ||
| Q2 24 | $3.9B | $13.4B | ||
| Q1 24 | $3.9B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-80.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-133.2M | $161.8M |
| 自由现金流率自由现金流/营收 | -12.8% | 21.0% |
| 资本支出强度资本支出/营收 | 5.1% | 2.6% |
| 现金转化率经营现金流/净利润 | -2.19× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $323.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流FIVERVTY
| Q4 25 | $-80.1M | $182.0M | ||
| Q3 25 | $93.0M | $138.5M | ||
| Q2 25 | $132.7M | $134.3M | ||
| Q1 25 | $363.5M | $128.2M | ||
| Q4 24 | $-30.6M | $174.2M | ||
| Q3 24 | $71.3M | $147.9M | ||
| Q2 24 | $26.4M | $158.6M | ||
| Q1 24 | $407.7M | $147.6M |
自由现金流FIVERVTY
| Q4 25 | $-133.2M | $161.8M | ||
| Q3 25 | $48.3M | $120.0M | ||
| Q2 25 | $96.5M | $115.5M | ||
| Q1 25 | $311.4M | $112.2M | ||
| Q4 24 | $-111.0M | $149.8M | ||
| Q3 24 | $-32.4M | $125.6M | ||
| Q2 24 | $-61.4M | $136.6M | ||
| Q1 24 | $304.6M | $129.7M |
自由现金流率FIVERVTY
| Q4 25 | -12.8% | 21.0% | ||
| Q3 25 | 4.7% | 17.2% | ||
| Q2 25 | 9.9% | 16.0% | ||
| Q1 25 | 22.4% | 16.9% | ||
| Q4 24 | -13.2% | 20.5% | ||
| Q3 24 | -3.9% | 18.4% | ||
| Q2 24 | -7.6% | 19.7% | ||
| Q1 24 | 22.8% | 20.0% |
资本支出强度FIVERVTY
| Q4 25 | 5.1% | 2.6% | ||
| Q3 25 | 4.4% | 2.6% | ||
| Q2 25 | 3.7% | 2.6% | ||
| Q1 25 | 3.7% | 2.4% | ||
| Q4 24 | 9.5% | 3.4% | ||
| Q3 24 | 12.5% | 3.3% | ||
| Q2 24 | 10.8% | 3.2% | ||
| Q1 24 | 7.7% | 2.7% |
现金转化率FIVERVTY
| Q4 25 | -2.19× | 1.85× | ||
| Q3 25 | 2.17× | 2.97× | ||
| Q2 25 | 3.22× | 2.49× | ||
| Q1 25 | 1.94× | 3.03× | ||
| Q4 24 | -18.13× | 1.84× | ||
| Q3 24 | 2.16× | 1.57× | ||
| Q2 24 | 0.84× | 2.87× | ||
| Q1 24 | 2.02× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FIVE
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
